The global small molecule drug discovery outsourcing market size accounted for USD 8.9 billion in 2025 and is predicted to increase from USD 9.67 billion in 2026 to approximately USD 20.5 billion by 2035, expanding at a CAGR of 8.7% from 2026 to 2035. Enhancement in AI-powered solutions, affordability, & specialized personnel by CROs is impelling outsourcing.
Market Highlight
Nowadays, robust pharmaceutical companies are contracting with external Contract Research Organizations (CROs) to manage stages of the development of low molecular weight, cell-permeable therapeutic compounds, which is referred to as the small molecule drug discovery outsourcing market. These firms widely facilitate expertise in medicinal chemistry, AI-powered lead optimization, & high-throughput screening, which ultimately surges research, lowers expenditures, & provides access to specialized 3D cell-based assays.
Market Approaching
In the future era, CROs will foster the adoption of AI for virtual screening & predictive modeling to accelerate lead identification & decline lab reliance. Alongside, the market has been stepping towards the transformation of 3D cell cultures, i.e. organoids/spheroids, target validation, & CRISPR-based functional genomics, specifically in oncology and immunology.
Number of Molecules Approved in 2024 & 2025 by the FDA
As per the above data, the FDA is actively pushing drug approvals, particularly in the oncology sector. These novel molecules highly emphasise RNA targeting, molecular degraders, i.e., similar to PROTACs, & deuterated molecules for enhanced stability, with steps towards fulfilling escalating demand for the rising cancer cases & targeted therapies.
Market Segmentation Overview
- By the drug discovery phase, the preclinical development segment held a major share of 23% of the small molecule drug discovery outsourcing market in 2025. This majorly covers GLP toxicology, safety pharmacology, & pharmacokinetic studies, with AI/ML integration. Ongoing advances are incorporating AI in molecular designing, in silico ADMET screening, & predictive modeling.
- By service type, the medicinal chemistry services segment led with 28% share in 2025. Globally rising demand for lead optimization & skilled chemists is driving outsourcing with minimal expenditures. Companies are spurring rapid library synthesis, i.e., around 20–200+ compounds for SAR development within 1–4 weeks, which uses photo redox chemistry & microscale synthesis.
- By therapeutic area, the oncology segment dominated with 32% share of the small molecule drug discovery outsourcing market and is estimated to grow at the fastest CAGR of 9.4% during the forecast period, due to the massive burden of cancer cases, which are highly demanding advanced, novel targeted therapies. For this, CROs are increasingly providing in vivo models & biomarker-driven screening to the worldwide companies. Also, targeting complex, high-potency molecules (HPAPIs) & hard-to-target proteins that need specialized containment & managing capabilities.
- By end user, the pharmaceutical companies segment captured 44% revenue share of the market in 2025. A substantial shift towards strategic, long-term alliances with supportive providers is facilitating end-to-end services from discovery to CMC (Chemistry, Manufacturing, and Controls), impacting outsourcing in these firms. Alongside, companies are leveraging CRDMO models & the China plus one strategy.
Regional Analysis
North America Market Trends
North America was dominant with 38% share of the small molecule drug discovery outsourcing market in 2025. This dominance is propelled by the extensive R&D spending and higher technological adoption. This region has a robust pharma hub, where diverse firms are highly demanding comprehensive, ‘all-in-one’ CRO partners to handle everything from hit generation to IND filing, & also lower vendor management difficulty. Besides this, Canadian companies are extensively leveraging AI for virtual screening & synthesis planning to speed up drug candidate identification
Asia Pacific Market Trends
Asia Pacific held 27% share in 2025 & is expected to witness rapid growth at 10.5% CAGR, due to the huge pool of specialized expertise. Whereas, China & India are developing as a CRO center, with a key emphasis on ADC leadership. Many Indian CROs are moving from order takers to problem solvers, which offer integrated medicinal chemistry, ADME, & toxicology services. Specifically, Chinese labs are leading in new drug development, especially in oncology, while 46% of novel molecules arriving global human trials in H1 2025 originate from Chinese biopharma.
Top Companies in the Small Molecule Drug Discovery Outsourcing Market
The leading 4 CROs are WuXi AppTec, Charles River Laboratories, Evotec, and Pharmaron in 2025. Whereas, WuXi has empowered its dry and wet lab integration, with AI, which assists the complete workflow for First-in-Class drug discovery, along with XDCs, PROTACs, & molecular glues.
Segments Covered in the Report
By Drug Discovery Phase
- Target Identification & Validation
- Genomics-based Target Identification
- Proteomics-based Target Identification
- High-Throughput Screening (HTS)
- Virtual Screening
- Hit Identificatio
- Lead Generation
- Lead Optimization (Early Stage)
- Hit-to-Lead (H2L)
- Preclinical Development
- ADME Studies
- Toxicology Studies
By Service Type
- Medicinal Chemistry Services
- Biology Services
- In Vitro Biology
- In Vivo Biology
- DMPK Services
- Pharmacokinetics
- Toxicokinetics
- Computational Chemistry
- Molecular Modeling
- AI/ML Drug Design
- Analytical & Bioanalytical Service
By Therapeutic Area
- Oncology
- Solid Tumors
- Hematologic Malignancies
- Cardiovascular Diseases
- Neurological Disorders
- Alzheimer’s Disease
- Parkinson’s Disease
- Infectious Diseases
- Metabolic Disorders
- Others
By End User
- Pharmaceutical Companies
- Large Pharma
- Mid-sized Pharma
- Biotechnology Companies
- Early-stage Biotech
- Established Biotech
- Academic & Research Institutes
- Contract Research Organizations (CROs)
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Europe
- Western Europe
- Germany
- Italy
- France
- Netherlands
- Spain
- Portugal
- Belgium
- Ireland
- UK
- Iceland
- Switzerland
- Poland
- Rest of Western Europe
- Eastern Europe
- Austria
- Russia & Belarus
- Türkiye
- Albania
- Rest of Eastern Europe
- Asia Pacific
- China
- Taiwan
- India
- Japan
- Australia and New Zealand
- ASEAN Countries (Singapore, Malaysia)
- South Korea
- Rest of APAC
- MEA
- GCC Countries
- Saudi Arabia
- United Arab Emirates (UAE)
- Qatar
- Kuwait
- Oman
- Bahrain
- South Africa
- Egypt
- Rest of MEA
